Press release
ALK-positive Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
ALK-positive Non-Small Cell Lung Cancer Pipeline
Key Takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's ALK-positive Non-Small Cell Lung Cancer pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for ALK-positive Non-Small Cell Lung Cancer treatment.
• The leading companies working in the ALK-positive Non-Small Cell Lung Cancer Market include GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutical, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.
• Promising ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Alkotinib Capsules, Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, X-396 capsule, and others.
• On June 2023, Pfizer announced a study of Phase 1 & 2 Clinical Trials for PF-06463922 and Crizotinib. Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non-small cell lung cancer patients.
• On August 2023, Betta Pharmaceuticals Co. Ltd announced a study of Phase 2 Clinical Trials for X-396 capsule. The main purpose of the study is to evaluate safety and efficacy of X-396(Ensartinib) capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib. While exploring the relationship between biomarkers and drug efficacy and safety.
Request a sample and discover the recent advances in ALK-positive Non-Small Cell Lung Cancer Treatment Drugs @ ALK-positive Non-Small Cell Lung Cancer Pipeline Report- https://www.delveinsight.com/report-store/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The ALK-positive Non-Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage ALK-positive Non-Small Cell Lung Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the ALK-positive Non-Small Cell Lung Cancer clinical trial landscape.
ALK-positive Non-Small Cell Lung Cancer Overview
ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it's a gene rearrangement-a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4).
Find out more about ALK-positive Non-Small Cell Lung Cancer Treatment Drugs @ Drugs for ALK-positive Non-Small Cell Lung Cancer Treatment- https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile
• Ensartinib: Betta Pharmaceuticals/Xcovery
• TQ-B3139 - Chia Tai Tianqing Pharmaceutical Group
ALK-positive Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for ALK-positive Non-Small Cell Lung Cancer. The ALK-positive Non-Small Cell Lung Cancer companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Betta Pharmaceuticals/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, Pfizer etc.
Learn more about the emerging ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies @ ALK-positive Non-Small Cell Lung Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report
• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• ALK-positive Non-Small Cell Lung Cancer Companies- GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutical, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.
• ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies- Alkotinib Capsules, Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, X-396 capsule, and others.
Dive deep into rich insights for new drugs for ALK-positive Non-Small Cell Lung Cancer Treatment, Visit @ ALK-positive Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. ALK-positive Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. ALK-positive Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. ALK-positive Non-Small Cell Lung Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Ensartinib: Betta Pharmaceuticals/Xcovery
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Bintrafusp alfa: EMD Serono/GlaxoSmithKline/Merck
14. Early Stage Products (Phase I)
15. PLB1003: Beijing Pearl Biotechnology Limited Liability Company
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. Drug profiles in the detailed report…..
19. Inactive Products
20. ALK-positive Non-Small Cell Lung Cancer Key Companies
21. ALK-positive Non-Small Cell Lung Cancer Key Products
22. ALK-positive Non-Small Cell Lung Cancer- Unmet Needs
23. ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. ALK-positive Non-Small Cell Lung Cancer Analyst Views
26. ALK-positive Non-Small Cell Lung Cancer Key Companies
27. Appendix
For further information on the ALK-positive Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to ALK-positive Non-Small Cell Lung Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Important Published Links-
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/45816438
https://council-of-light.mn.co/posts/45816468
https://chanspirations.mn.co/posts/45816726
https://hulu-com-forgot.mn.co/posts/45816832
https://bucketseems-news.mn.co/members/20271966
https://sentinels.mn.co/members/20272156
https://akademe.mn.co/posts/navigating-the-acne-vulgaris-market-trends-treatments-and-technological-advances
https://tc-2345.mn.co/posts/45818004
https://gene-keys-genealogy.mn.co/posts/45818150
https://take-your-phone.mn.co/posts/45818381
https://digitaldrip.mn.co/posts/45818561
https://network-24921.mn.co/posts/45818644
https://friends-of-zizira.mn.co/members/20272206
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ALK-positive Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated) here
News-ID: 3300732 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for ALK
ALK ELISA Kits Market Outlook and Future Projections for 2030
The alk elisa kits market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
ALK-1 Antibody Market Outlook and Future Projections for 2030
The alk-1 antibody market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the current…
ALK-positive Non-Small Cell Lung Cancer Pipeline: Companies Advancing Targeted T …
The therapeutic landscape for ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC), a genetically defined subset of lung cancer driven by ALK gene rearrangements, is undergoing a significant transformation. Biopharmaceutical companies are shifting focus from traditional chemotherapy to precision medicine approaches that directly inhibit ALK-driven oncogenic signaling. With multiple generations of ALK inhibitors now available and resistance mechanisms emerging, the spotlight is on next-generation inhibitors, combination regimens, and CNS-penetrant therapies designed…
Allergy Shots Market | ALK Abello, Aimmune Therapeutics, Allergy Therapeutics, A …
The global allergy shots market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the allergy shots market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Analysis By Major Manufa …
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the future. The information presented is based on historical milestones…
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market 2023: Analysis By Regional Outl …
Los Angeles, United State: The latest report published by QY Research presents a thorough analysis of the global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market. The research report evaluates the ever-changing market dynamics that are expected to impact the trajectory of the overall market. Analysts studied the historical achievements of the market and compared it to the current market trends, to chart the trajectory. For a detailed discussion about the global ALK Tyrosine…
